SLC2A1 and melanoma: For melanoma patients who underwent anti-PD1 therapy 23, the GLUT-ratio was positively correlated with ImmuneScore for both pre-treatment and on-treatment data (r = 0.23, p = 0.10 and r = 0.28, p = 0.03; Figure 5A, B).